---
date: 2026-10-10
source: user
asked_by: user
capture: verbatim
original_location: the user's chat messages of 2026-10-09 and 2026-10-10 in the claude-code sessions recorded by devlog 2026-10-09_protein-association-for-pavan, 2026-10-10_protein-association-for-pavan-v2 and 2026-10-10_decisions-new-run-inclusion-reweighting-lfs; Pavan's question reached the user by email and the user relayed it verbatim on 2026-10-09; all items were recorded here on 2026-10-10
---

# 2026-10-10 protein-data questions (Pavan and the user) and three user decisions for runs on the new patient data

Each quoted text is verbatim (wording and typos kept). A-20261010-01 and -02 were asked on 2026-10-09; the rest on 2026-10-10. The protein questions were answered in chat and by the v2 figures in `research/team_updates/2026-10-09_protein_association_for_pavan/` (devlog 2026-10-10_protein-association-for-pavan-v2). The decisions are recorded in devlog 2026-10-10_decisions-new-run-inclusion-reweighting-lfs.

## Protein data (D27, W5.3)

- [A-20261010-01] (teammate:Pavan) "have you been able to integrate the protein data?" -> W5.3, D27
- [A-20261010-02] "Wrt figure 13, my collaborator Pavan asked "have you been able to integrate the protein data?". I am going to reply that we haven't integrate the protein into the DR, but we can evaluate factors with protein association (not sure if association the correct word to use here), but basically we can email back this screenshot (let's do an update if possible, I need to understand what isotype max |rho| mean and CLR ADT is just the surface protein column from the .h5ad file?" -> W5, D27
- [A-20261010-03] "So the isotypes are in our data, how do you know they are isotypes, does the data annotate that? Why/how come we decide to use it to define noise?" -> W5, D27
- [A-20261010-04] "All the single cell is filtered through a CD34 gate. So that's probably the reason to see CD34 there, right?" -> W5, D27, H-S2-05
- [A-20261010-05] "What other surface protein tracks with healthy?" -> W5, D27
- [A-20261010-06] "What does 19 out of 20 within patient comparisons mean?" -> W5, D27

## Decisions for runs on the new patient data (W8.5, W2.3, W0.2)

- [A-20261010-07] "Let's do the >=100 malignant cells." -> W8, W8.5
- [A-20261010-08] "Reweight should target stage 2 label it sounds like that's more relevant" -> W2.3, H-S2-09
- [A-20261010-09] "I am not sure what's up with Git LFS line." -> W0.2
- [A-20261010-10] "Let's change the git LFS thing." -> W0.2

## Report and onboarding requests (W0, D26)

- [A-20261010-11] "Definitely trim, even 59 pages are a lot of the final report. I am not going to read 59 pages let along 82." -> W0
- [A-20261010-12] "In terms of sharing the repo, let's make sure that we are building something both human can easily start or if my collab also use agents, they can easily start understanding." -> W0.14, W0.15
- [A-20261010-13] "What did we do with allograft and apoptosis? Please update all that as a new section in the report." -> W0, D26

## Where each item is answered

| Ask | Short | Answered in | State to expect |
|---|---|---|---|
| A-20261010-01 | Pavan: is the protein data integrated? | Reply draft and figures v1/v2 (devlog 2026-10-09_protein-association-for-pavan, 2026-10-10_protein-association-for-pavan-v2): the protein is not integrated into Stage 1; factors are compared with surface proteins (D27) | partial until W5.3 is closed |
| A-20261010-02 | what "isotype max \|rho\|" and "CLR ADT" are | devlog 2026-10-09_protein-association-for-pavan (caption and the CLR definition) | answered |
| A-20261010-03 | how the isotypes are known; why they define noise | devlog 2026-10-10_protein-association-for-pavan-v2 (Figure 4 and its caption) | answered |
| A-20261010-04 | the CD34 sort and the CD34 correlate | devlog 2026-10-10_protein-association-for-pavan-v2 (Figure 2: between versus within cell type) | answered |
| A-20261010-05 | other healthy-cell proteins | devlog 2026-10-10_protein-association-for-pavan-v2 (Figure 1, healthy rows) | answered |
| A-20261010-06 | the "19 out of 20" count | devlog 2026-10-10_protein-association-for-pavan-v2 (Figure 3: one comparison per patient and cell type) | answered |
| A-20261010-07 | patient inclusion for new runs | devlog 2026-10-10_decisions-new-run-inclusion-reweighting-lfs (closes W8.5) | answered |
| A-20261010-08 | re-weighting target | the same entry (closes W2.3) | answered |
| A-20261010-09, -10 | the Git LFS lines | the same entry (closes W0.2; the push is W0.3) | answered |
| A-20261010-11 | trim the report | devlog 2026-10-10_core-report-v3 (the core report, at most 12 pages) | answered |
| A-20261010-12 | a repo humans and their agents can start in | devlog 2026-10-10_core-report-v3 (README.md and AGENTS.md onboarding); W0.15 (which figures and PDFs a clone carries) is still a user decision | partial until W0.15 is decided |
| A-20261010-13 | a report section on allograft rejection and apoptosis | devlog 2026-10-10_core-report-v3 (full report section 2b, core page 4; D26 results in 2026-10-10_d26-leverage-allograft-apoptosis-done) | answered |

## The two decision messages (verbatim)

> Let's do the >=100 malignant cells. Reweight should target stage 2 label it sounds like that's more relevant and I am not sure what's up with Git LFS line. These all sounds like decisions relevant for runs when we have the extra patient data. Definitely trim, even 59 pages are a lot of the final report. I am not going to read 59 pages let along 82. I submitted the leverage test on allograft and apoptosis (D26) run.

> Let's change the git LFS thing. In terms of sharing the repo, let's make sure that we are building something both human can easily start or if my collab also use agents, they can easily start understanding. What did we do with allograft and apoptosis? Please update all that as a new section in the report.

The sentence "These all sounds like decisions relevant for runs when we have the extra patient data" scopes A-20261010-07 and -08: they govern the new-data runs (W8), not re-analyses of the current atlas. "I submitted the leverage test ... (D26) run" is recorded in devlog 2026-10-10_d26-leverage-allograft-apoptosis-done. The requests to trim the questions report, to make the repo easy to start for collaborators and their agents, and to add a report section on what was done with allograft rejection and apoptosis were first left without A-IDs; they were added on 2026-10-10 as A-20261010-11..13 (AGENTS.md §2 step 6).
